Emerging Pharmacotherapies for Diabetic Macular Edema

Table 1

Selected clinical trials of corticosteroids in treatment of diabetic macular edema.

Agent (no. patients)	Main outcomes	Reference
Intravitreal triamcinolone (693)	Less favorable outcomes versus photocoagulation at 24 and 36 months	[22, 23]
Peribulbar triamcinolone (109)	Less favorable outcomes versus intravitreal triamcinolone at 34 weeks	[28]
Fluocinolone acetonide implant (Retisert) (197)	Effective treatment of DME at 36 months, but high risks of cataract and glaucoma	[32]
Fluocinolone acetonide implant (Iluvien) (956)	Generally favorable results at 24 months	[34]
Dexamethasone drug delivery system (Ozurdex) (171)	Generally favorable results at 90 days	[36]